NCT02230202|Completed
Loading search results
Sponsor study identifier
Secondary identifiers
NIH
observational
90
1 country
2
Study Start
September 2014
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2016
Actual (reported)Study Completion
March 2016
Actual (reported)The primary hypothesis of this proposal is that chronic kidney disease (CKD) and treatment with calcineurin inhibitors (CNIs) are each associated with the release of endothelial microparticles into the plasma.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2016
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 25, 2014
Actual (reported)September 2014
Date type not reportedThis date has not been verified as actual or estimated.
September 3, 2014
Actual (reported)March 2016
Actual (reported)March 2016
Actual (reported)Change in Vascular Function
This will be measured with flow-mediated dilation and evaluate percent change from baseline over minutes.
percent change from baseline over 2 minutes
Characterization of Microparticle source from blood analysis
Single time point
Healthy control that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
Stage III or IV CKD patients that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
Stage III or IV CKD Post-transplant patients that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
Flow-mediated dilation used to measure vascular function. The test is minimally invasive, with only a slight discomfort due to the inflation of the arm cuff.
90 volunteers from the Anschutz Medical Campus
University of Colorado Anschutz Medical Campus; CTRC
Aurora, Colorado, 80045, United States
University of Colorado School of Medicine
Aurora, Colorado, 80045, United States
Jalal D, Renner B, Laskowski J, Stites E, Cooper J, Valente K, You Z, Perrenoud L, Le Quintrec M, Muhamed I, Christians U, Klawitter J, Lindorfer MA, Taylor RP, Holers VM, Thurman JM. Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease. J Am Heart Assoc. 2018 Jul 13;7(14):e007818. doi: 10.1161/JAHA.117.007818.
plasma and urine biospecimens to be retained.
Joshua M Thurman, MD
University of Colorado, Denver
90 participants (actual enrollment reported by the registry).
First Submitted
August 25, 2014
First Posted
September 3, 2014
Study Start
September 2014
Date type not reportedThis date has not been verified as actual or estimated.
Resistance Exercise Training in Chronic Kidney Disease
single blood draw of approximately 45 mL.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
March 2016
Actual (reported)Study Completion
March 2016
Actual (reported)Last Updated
February 28, 2018
Record last verified: 2018-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: